In vivo combination therapy with anti-PD1 or anti-CTLA4 testing

monoclonal ab 300x225

Service description

  • This type of therapy allows the targeting of mechanisms or pathways that have an important role in the development of cancers.
  • In vivo tests provide a means of evaluating the effectiveness of these PD1 or CTLA4 therapies.
  • Tumor cells are injected subcutaneously. When the size of the tumor is reached, antibody injections and tumor progression allow the effectiveness of the treatment to be monitored.

Materials to provide

  • Samples.

  • Further details on the project may be requested.
  • You will be able to exchange directly with the experts after filling in the form below.

Typical deliverables

  • Study following the specifications validated with the Expert.
Capture d’écran 2020-10-16 à 10.57.43

Get started with your in vivo combination therapy testing project

Please answer the fields below to be contacted by our team of scientists

favicon large un peu plus-1